India, Nov. 3 -- bioMerieux S.A. (BIM.PA), a diagnostics company, on Monday reported financial results from the third quarter, noting a significant sales growth and confirmed earnings guidance for the full year of 2026.
The company provides in vitro diagnostics services through systems, reagents and software to determine the source of a disease, protect patient health and ensure consumer safety standards. Additionally, its labs also detect microorganisms in agri-food, pharmaceuticals, and cosmetic products.
Among its marketed products are the BIOFIRE syndromic tests, which provide an array of rapid PCR tests to identify an infectious pathogen. The SPOTFIRE PCR tests are an offshoot of BIOFIRE and provide specialized diagnostics for respir...